Publication | Closed Access

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial

OncologyDisease ProgressionSecond Interim AnalysisMetronomic TherapyClinical TrialsBronchial NeoplasmCancer TreatmentMedicineRadiation OncologyLung CancerRadiologyHealth Sciences